Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics

dc.authorid0000-0003-4190-3962
dc.authorid0000-0001-8096-6056
dc.authorid0000-0003-0560-1895
dc.authorid0000-0002-9115-275X
dc.authorid0000-0002-3791-838X
dc.authorid0000-0003-0427-3519
dc.authorid0000-0002-4173-6634
dc.contributor.authorBerber, Burak
dc.contributor.authorAydin, Cihan
dc.contributor.authorKocabas, Fatih
dc.contributor.authorGuney-Esken, Gulen
dc.contributor.authorYilancioglu, Kaan
dc.contributor.authorKaradağ-Alpaslan, Medine
dc.contributor.authorCaliseki, Mehmet
dc.date.accessioned2025-05-10T19:44:15Z
dc.date.issued2021
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractThe novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9-13, Lancet 2020;395:497-506, N. Engl J Med 2020a;382:1199-207, Nature 2020;579:270-3). SARS-CoV-2 surveillance is essential to controlling widespread transmission. However, there are several challenges associated with the diagnostic of the COVID-19 during the current outbreak (Liu and Li (2019), Nature 2020;579:265-9, N. Engl J Med 2020;382:727-33). Firstly, the high number of cases overwhelms diagnostic test capacity and proposes the need for a rapid solution for sample processing (Science 2018;360:444-8). Secondly, SARS-CoV-2 is closely related to other important coronavirus species and subspecies, so detection assays can give false-positive results if they are not efficiently specific to SARS-CoV-2. Thirdly, patients with suspected SARS-CoV-2 infection sometimes have a different respiratory viral infection or co-infections with SARS-CoV-2 and other respiratory viruses (MedRxiv 2020a;1-18). Confirmation of the COVID-19 is performed mainly by virus isolation followed by RT-PCR and sequencing (N. Engl J Med 2020;382:727-33, MedRxiv 2020a, Turkish J Biol 2020;44:192-202). The emergence and outbreak of the novel coronavirus highlighted the urgent need for new therapeutic technologies that are fast, precise, stable, easy to manufacture, and target-specific for surveillance and treatment. Molecular biology tools that include gene-editing approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, antisense oligonucleotides, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing approaches produced with cutting-edge scientific advances compared to conventional diagnostic or treatment methods could be vital in COVID-19 and other future outbreaks. Thus, in this review, we will discuss potent the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way.
dc.identifier.doi10.1038/s41434-020-00209-7
dc.identifier.endpage305
dc.identifier.issn0969-7128
dc.identifier.issn1476-5462
dc.identifier.issue6
dc.identifier.pmid33318646
dc.identifier.scopus2-s2.0-85105424610
dc.identifier.scopusqualityQ1
dc.identifier.startpage290
dc.identifier.urihttps://doi.org/10.1038/s41434-020-00209-7
dc.identifier.urihttps://hdl.handle.net/20.500.14730/10880
dc.identifier.volume28
dc.identifier.wosWOS:000598702600001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringernature
dc.relation.ispartofGene Therapy
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectPeptide Nucleic-Acids
dc.subjectRespiratory Syndrome Coronavirus
dc.subjectPrimer Binding-Site
dc.subjectVirus In-Vitro
dc.subjectAntisense Oligonucleotides
dc.subjectGuide Rnas
dc.subjectInhibition
dc.subjectTherapy
dc.subjectSars
dc.subjectRibozymes
dc.titleGene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
dc.typeReview

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10880.pdf
Boyut:
1.18 MB
Biçim:
Adobe Portable Document Format